Breaking News

AbbVie Launches New Biopharma Company

January 2, 2013

Resumes Abbott’s research-based business

AbbVie has launched as an independent biopharmaceutical company, as Abbott completed the separation from the research arm of its pharmaceutical business.
 
AbbVie launches with an estimated $18 billion in annual revenues, a team of experienced senior leaders, and a broad portfolio that includes Humira, AndroGel, Lupron, Synagis, Creon, Synthroid, Kaletra, Norvir and Zemplar. The company will also keep the Abbott Contract Manufacturing business.
 
"Today AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth," said Richard A. Gonzalez, chairman of the board and chief executive officer, AbbVie. "With those assets and a relentless focus on innovation we intend to create significant value for our shareholders."
 
"We wish our colleagues at AbbVie continued success as they become part of a new, independent company that is already making a significant difference, focusing on highly specialized, market-leading therapies for some of the world's most difficult-to-treat diseases," said Miles D. White, chairman and chief executive officer, Abbott.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks